Why You Should Break Up with Your Biobank The initial excitement and growth of biobanks worldwide has faced several challenges related to logistics, ethics, and utility, 1,2 which call into question the long-term feasibility of a relationship with the traditional biobank. Perhaps it already feels one-sided, transactional, and unbalanced when trying to fulfill the many needs of a research study design. Particularly when trying to obtain broad consent from participants for future research, getting support for a longitudinal study, complex inclusion and exclusion criteria, or fresh sample collection and same-day delivery. So, here’s why we are saying you should break it off.
Precision Medicine for Genetic Disease: from Prevention to Treatment Jun Liao, Ph.D., FACMG, Laboratory Director and Assistant Professor @Columbia University Medical Center
COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses Sahin, Muik, Derhovanessian et al Nature (2020)
Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults Mulligan, Lyke, Kitchin et al Nature (2020)
